|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00224523 |
|
Date of registration:
|
26/08/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Long Term Safety Of GW685698X Via Nasal Biopsy
|
|
Scientific title:
|
See Detailed Description |
|
Date of first enrolment:
|
September 2005 |
|
Target sample size:
|
125 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00224523 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Belgium
|
Netherlands
| | | | | | |
|
Contacts
|
|
Name:
|
GSK Clinical Trials, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
GlaxoSmithKline |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
- History of perennial allergic rhinitis of 2 years, with a documented positive
allergen test to an appropriate allergen.
- Female patients of child-bearing potential must be willing to consistently and
correctly use an acceptable method of birth control.
Exclusion criteria:
- Patients who require certain medications for their allergy.
- Patients with serious medical problems.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Perennial Allergic Rhinitis
|
|
Intervention(s)
|
|
Drug: GW685698X
|
|
Drug: mometasone furoate
|
|
Primary Outcome(s)
|
|
Quantitative and qualitative differences in the morphology and cytology of the nasal mucosa after 1 year of treatment.
|
|
Secondary Outcome(s)
|
|
No Secondary Outcome Measures
|
|
Secondary ID(s)
|
|
FFR104503
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|